Vitrolife AB announced on Friday that Bronwyn Brophy O’Connor has chosen to step down as chief executive officer to assume a CEO role in another segment of the medtech industry.
The company said the board has accepted her resignation and that it will begin an immediate search for a successor with assistance from international recruitment specialists. The search will include consideration of both internal and external candidates.
Brophy O’Connor is set to remain in her role during a notice period that may extend to 12 months. The company framed the extended notice as a means to secure an orderly transfer of responsibilities and to provide continuity while the board completes its recruitment process.
"We have seen Bronwyn develop as a leader, and we are proud to have been part of her journey. As she takes the next step toward an exciting new role, we recognize this as a great opportunity for her and respect her decision. We wish Bronwyn every success in her future endeavors,"
Jón Sigurdsson, Chairman of the Board, expressed gratitude for Brophy O’Connor’s service, noting her development during three years at the company's helm.
"Leading the Vitrolife Group is an honor and a privilege. I will miss our fantastic colleagues around the world, and the vision we share to enable people to fulfill the dream of having a healthy baby. Vitrolife Group is truly on a path to becoming the leading global partner in reproductive health. In the next phase of my career, I will join a renowned company, in a different area of the medtech industry at an exciting time in its history,"
Brophy O’Connor described her decision as made with mixed feelings, emphasizing both her connection to Vitrolife’s global workforce and the company’s stated objective of becoming a leading partner in reproductive health.
Context and immediate actions
The board has engaged international recruitment specialists to support the search. By naming the approach as immediate and by signaling that candidates both inside and outside the company will be evaluated, Vitrolife has indicated a broad search strategy. The CEO’s extended availability through a potential 12-month notice period provides the board flexibility to manage the selection and handover process.
What the statement confirms
- Brophy O’Connor will leave Vitrolife to take on a CEO position in another area of the medtech industry.
- She will remain available in her current role for up to 12 months during her notice period to facilitate a transition.
- The board has accepted her resignation and will immediately start recruiting a successor with assistance from international recruiters, considering both internal and external candidates.
The announcement reiterates Vitrolife’s focus on reproductive health while acknowledging a forthcoming change in leadership. Beyond the steps detailed by the company, the statement provides no additional timelines or names related to the recruitment process.